These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 27494117)
1. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14. Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117 [TBL] [Abstract][Full Text] [Related]
2. Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. Cho Y; Cho EJ; Lee JH; Yu SJ; Kim YJ; Kim CY; Yoon JH Biomed Pharmacother; 2016 Oct; 83():607-616. PubMed ID: 27459117 [TBL] [Abstract][Full Text] [Related]
3. Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers. Rong Y; Chen H; Zhou XF; Yin CQ; Wang BC; Peng CW; Liu SP; Wang FB Oncotarget; 2016 Feb; 7(7):8282-94. PubMed ID: 26882565 [TBL] [Abstract][Full Text] [Related]
4. Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment. Liang X; Wang Y; Shi H; Dong M; Han H; Li Q Int J Nanomedicine; 2021; 16():2569-2584. PubMed ID: 33833512 [TBL] [Abstract][Full Text] [Related]
5. AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin. Cheng Y; Zhao G; Zhang S; Nigim F; Zhou G; Yu Z; Song Y; Chen Y; Li Y PLoS One; 2016; 11(12):e0167094. PubMed ID: 27907160 [TBL] [Abstract][Full Text] [Related]
6. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo. Yao M; Wang L; Yang J; Yan X; Cai Y; Yao D Tumour Biol; 2016 Nov; 37(11):14677-14686. PubMed ID: 27623941 [TBL] [Abstract][Full Text] [Related]
7. Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. Fujita K; Iwama H; Sakamoto T; Okura R; Kobayashi K; Takano J; Katsura A; Tatsuta M; Maeda E; Mimura S; Nomura T; Tani J; Miyoshi H; Morishita A; Yoneyama H; Yamana Y; Himoto T; Okano K; Suzuki Y; Niki T; Hirashima M; Masaki T Int J Oncol; 2015; 46(6):2419-30. PubMed ID: 25823465 [TBL] [Abstract][Full Text] [Related]
8. miR-15b-5p induces endoplasmic reticulum stress and apoptosis in human hepatocellular carcinoma, both in vitro and in vivo, by suppressing Rab1A. Yang Y; Hou N; Wang X; Wang L; Chang S; He K; Zhao Z; Zhao X; Song T; Huang C Oncotarget; 2015 Jun; 6(18):16227-38. PubMed ID: 26023735 [TBL] [Abstract][Full Text] [Related]
9. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871 [TBL] [Abstract][Full Text] [Related]
10. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy. Zuo M; Li C; Lin J; Javle M Oncotarget; 2015 May; 6(13):10940-9. PubMed ID: 25883212 [TBL] [Abstract][Full Text] [Related]
11. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1. Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710 [TBL] [Abstract][Full Text] [Related]
12. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114 [TBL] [Abstract][Full Text] [Related]
13. Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma. Zhao J; Lin W; Cao Z; Liu L; Zhuang Q; Zhong X; Hong Z; Peng J Oncol Rep; 2013 Sep; 30(3):1309-14. PubMed ID: 23828071 [TBL] [Abstract][Full Text] [Related]
14. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice. Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751 [TBL] [Abstract][Full Text] [Related]
15. Bioactivity of 2'-deoxyinosine-incorporated aptamer AS1411. Fan X; Sun L; Wu Y; Zhang L; Yang Z Sci Rep; 2016 May; 6():25799. PubMed ID: 27194215 [TBL] [Abstract][Full Text] [Related]
16. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-β. Li HP; Zeng XC; Zhang B; Long JT; Zhou B; Tan GS; Zeng WX; Chen W; Yang JY Carcinogenesis; 2013 Nov; 34(11):2443-51. PubMed ID: 23740840 [TBL] [Abstract][Full Text] [Related]
17. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression. Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061 [TBL] [Abstract][Full Text] [Related]
18. Auphen and dibutyryl cAMP suppress growth of hepatocellular carcinoma by regulating expression of aquaporins 3 and 9 in vivo. Peng R; Zhao GX; Li J; Zhang Y; Shen XZ; Wang JY; Sun JY World J Gastroenterol; 2016 Mar; 22(12):3341-54. PubMed ID: 27022216 [TBL] [Abstract][Full Text] [Related]
19. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma. Hirata H; Sugimachi K; Komatsu H; Ueda M; Masuda T; Uchi R; Sakimura S; Nambara S; Saito T; Shinden Y; Iguchi T; Eguchi H; Ito S; Terashima K; Sakamoto K; Hirakawa M; Honda H; Mimori K Cancer Res; 2016 Jun; 76(11):3265-76. PubMed ID: 27197151 [TBL] [Abstract][Full Text] [Related]
20. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma. Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]